Show simple item record

dc.contributor.authorZhao, Sizheng Steven
dc.contributor.authorYoshida, Kazuki
dc.contributor.authorJones, Gareth T.
dc.contributor.authorHughes, David M.
dc.contributor.authorDuffield, Stephen J.
dc.contributor.authorTedeschi, Sara K.
dc.contributor.authorLyu, Houchen
dc.contributor.authorMoots, Robert J.
dc.contributor.authorSolomon, Daniel H.
dc.contributor.authorGoodson, Nicola J.
dc.date.accessioned2019-08-28T13:10:08Z
dc.date.available2019-08-28T13:10:08Z
dc.date.issued2019-07-22
dc.identifier147102016
dc.identifierae4a5520-dcde-4716-b15e-81e522bf67ee
dc.identifier31331375
dc.identifier000476712900001
dc.identifier85069759314
dc.identifier.citationZhao , S S , Yoshida , K , Jones , G T , Hughes , D M , Duffield , S J , Tedeschi , S K , Lyu , H , Moots , R J , Solomon , D H & Goodson , N J 2019 , ' Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis ' , Arthritis Research & Therapy , vol. 21 , no. 1 , 177 . https://doi.org/10.1186/s13075-019-1958-zen
dc.identifier.issn1478-6354
dc.identifier.otherPubMedCentral: PMC6647300
dc.identifier.otherMendeley: 2c082130-ea08-36a1-a666-a867c4731854
dc.identifier.otherORCID: /0000-0003-0016-7591/work/83703976
dc.identifier.urihttp://hdl.handle.net/2164/12801
dc.descriptionAvailability of data and materials BSRBR-AS data are held at the University of Aberdeen. Funding The BSRBR-AS is funded by the British Society for Rheumatology (BSR) who have received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments. They have no input in determining the topics for analysis or work involved in undertaking it. SZ was supported by awards from the Royal College of Physicians (John Glyn bursary) and Royal Society of Medicine (Kovacs fellowship). KY received financial support for his doctoral study from the Pharmacoepidemiology Program at the Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer and ASISA) and Honjo International Scholarship Foundation. DHS was supported by grants from the National Institute of Health (NIH-P30-AR072577 (VERITY) and NIH-K24AR055989) and has received funding from Abbvie and Amgen unrelated to this work. Acknowledgements We are grateful to Professor Gary Macfarlane (Chief Investigator of BSRBR-AS) and the staff of the BSRBR-AS register who are currently Claudia Zabke, Elizabeth Ferguson-Jones, Maureen Heddle, Nafeesa Nazlee and Barry Morris, and to the recruiting staff at the clinical centres, details of which are available at: https://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritisen
dc.format.extent7
dc.format.extent585366
dc.language.isoeng
dc.relation.ispartofArthritis Research & Therapyen
dc.subjectAxial spondyloarthritisen
dc.subjectTNF inhibitoren
dc.subjectBiologic DMARDsen
dc.subjectPersistenceen
dc.subjectEffectivenessen
dc.subjectResponseen
dc.subjectDiscontinuationen
dc.subjectMarginal structural modelen
dc.subjectR Medicine (General)en
dc.subjectSupplementary Dataen
dc.subject.lccR1en
dc.titleSmoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritisen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Epidemiology Groupen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Arthritis and Musculoskeletal Health (ACAMH)en
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1186/s13075-019-1958-z
dc.identifier.urlhttp://www.mendeley.com/research/smoking-status-causespecific-discontinuation-tumour-necrosis-factor-inhibitors-axial-spondyloarthriten
dc.identifier.vol21en
dc.identifier.iss1en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record